Danske Bank A S Purchases New Shares in Insulet Corporation $PODD

Danske Bank A S purchased a new stake in Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 45,908 shares of the medical instruments supplier’s stock, valued at approximately $6,989,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. NewEdge Advisors LLC boosted its stake in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 64 shares during the period. Cresset Asset Management LLC increased its holdings in shares of Insulet by 7.3% during the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares during the period. Cerity Partners LLC increased its holdings in shares of Insulet by 68.7% during the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares during the period. Sei Investments Co. raised its position in shares of Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after buying an additional 29,584 shares in the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in Insulet by 2.5% in the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after purchasing an additional 791 shares during the period.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on PODD shares. Evercore set a $180.00 target price on Insulet in a report on Monday, July 6th. Stifel Nicolaus reduced their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Canaccord Genuity Group dropped their target price on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company lowered shares of Insulet from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $255.00 to $144.00 in a research note on Wednesday, August 5th. Finally, Truist Financial reissued a “hold” rating and set a $153.00 price objective (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $195.40.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Pomerantz said a class action has been filed in the U.S. District Court for the District of Massachusetts under docket 26-cv-13062. The proposed class generally covers investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and seeks damages under Sections 10(b) and 20(a) of the Securities Exchange Act. Pomerantz class action filing
• Neutral Sentiment: Several law firms—including DJS Law Group, Schall Brown & Schwartz, Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, and Bernstein Liebhard—reminded shareholders of an August 31 deadline to seek appointment as lead plaintiff. These announcements are primarily investor solicitations rather than new operational developments. Robbins Geller investor deadline
• Negative Sentiment: The allegations center on purportedly false or misleading statements about Insulet’s manufacturing quality and product safety. One investor notice linked the claims to two Omnipod medical-device corrections and reported substantial share-price declines following corrective disclosures. If the case advances, Insulet could face litigation expenses, potential damages, reputational harm, and additional scrutiny of its products and disclosures. Insulet shareholder lawsuit allegations

Insulet Trading Up 0.9%

Shares of NASDAQ:PODD opened at $148.16 on Friday. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $10.27 billion, a PE ratio of 27.69, a P/E/G ratio of 1.16 and a beta of 1.10. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88. The firm has a fifty day moving average price of $154.67 and a 200 day moving average price of $184.81.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period last year, the company earned $1.17 earnings per share. The business’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts expect that Insulet Corporation will post 6.51 EPS for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.